FOX04-DRI
Also known as: FOXO4-DRI, FOXO4-D-retro-inverso
Grey-Market Compound. This compound is not approved by the FDA or any major regulatory authority. No established regimen exists. Products available outside of regulated channels lack standardized manufacturing, quality control, and potency verification. Consult a qualified clinician. Research-only risks apply.
Overview
Clinical Summary
FOX04-DRI is a D-retro-inverso peptide that disrupts the interaction between FOXO4 and p53 in senescent cells. In healthy cells, p53 is free to induce apoptosis when appropriate, but in senescent cells, FOXO4 sequesters p53, preventing senescent cell death and allowing these cells to persist and secrete inflammatory factors (the senescence-associated secretory phenotype, or SASP). By disrupting FOXO4-p53 binding, FOX04-DRI selectively triggers apoptosis in senescent cells while sparing healthy cells. A single preclinical study in aged mice showed restoration of fitness, fur density, and renal function. No human studies have been conducted.
Plain Language Summary
FOX04-DRI is a research peptide designed to selectively kill senescent (or 'zombie') cells that accumulate as you age. These old, damaged cells stop dividing but refuse to die, instead releasing harmful inflammatory signals that damage nearby healthy tissue. FOX04-DRI works by releasing a 'death trigger' protein (p53) that is trapped inside senescent cells. In a mouse study, old mice treated with FOX04-DRI became more active and showed improved kidney function and fur regrowth. It has never been tested in humans.
Mechanism of Action
FOX04-DRI is a D-retro-inverso (DRI) peptide, meaning it uses D-amino acids in a reversed sequence to mimic the binding surface of the native FOXO4 protein while being resistant to protease degradation. In senescent cells, FOXO4 is upregulated and forms a complex with p53 in PML nuclear bodies, preventing p53 from initiating the apoptotic cascade. FOX04-DRI acts as a competitive inhibitor, displacing FOXO4 from p53. The released p53 then activates the mitochondrial (intrinsic) apoptotic pathway, triggering cytochrome c release and caspase activation specifically in senescent cells. Non-senescent cells have low FOXO4 expression and are therefore not affected by this mechanism.
Evidence Summary
Baar et al. (2017, Cell) published the sole preclinical study. In vitro, FOX04-DRI selectively induced apoptosis in doxorubicin-induced senescent human IMR90 fibroblasts while sparing proliferating cells. In vivo, treatment of fast-aging (XpdTTD/TTD) and naturally aged wild-type mice with FOX04-DRI reduced senescent cell burden, restored fur density, improved renal function (reduced plasma urea and creatinine), and increased running wheel activity. No independent replication has been published. No human pharmacokinetic, toxicology, or dosing data exist.
Safety Profile
No human safety data exist. The single mouse study did not report significant toxicity, but formal toxicology studies were not conducted. As a senolytic agent, theoretical concerns include: depletion of beneficial senescent cells (needed for wound healing and tumor suppression), unintended clearance of non-target cells, and immune-mediated reactions from mass senescent cell apoptosis. The DRI peptide backbone should resist proteolysis but may accumulate in tissues.
Contraindications
- No established contraindications due to absence of human data
- Theoretical concern during active wound healing (senescent cells contribute to repair)
- Theoretical concern in patients with compromised immune function
- Pregnancy and breastfeeding (no safety data)
Adverse Events
- No human adverse event data available
- Theoretical cytokine release from mass senescent cell clearance
- Theoretical impairment of wound healing
- Unknown off-target effects
Interactions
- No drug interaction data available
- Theoretical interaction with other senolytics (additive senescent cell clearance)
- May interact with chemotherapy agents (shared p53 pathway modulation)
Regulatory Notes
FOX04-DRI is a research-only compound with no regulatory approval. It has not entered clinical trials. The original research was conducted at Erasmus University Medical Center (Netherlands). It is available through grey-market peptide vendors, but the quality and purity of these preparations are unverified. The cost is extremely high due to the complexity of D-amino acid peptide synthesis.
Monitoring Considerations
No established monitoring guidelines. In a research context, senescence biomarkers (p16INK4a, SA-beta-galactosidase), inflammatory markers (SASP factors: IL-6, IL-8, MMP-3), renal function, and general hematology could be considered.
These are general considerations for clinical awareness and do not constitute prescriptive monitoring recommendations for any individual patient.
Stability and Handling Notes
DRI peptides are resistant to protease degradation, conferring enhanced stability compared to L-amino acid peptides. Grey-market preparations are supplied as lyophilized powder. Store at minus 20 degrees C. Reconstitute with bacteriostatic water. The D-amino acid composition makes FOX04-DRI expensive to synthesize, and grey-market products may be of questionable purity.
References
- 1preclinical
Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging
Baar MP, Braat H, Jager DC, et al. (2017). Cell
Key findings: FOX04-DRI disrupted the FOXO4-p53 interaction in senescent cells, selectively inducing apoptosis. In aged mice, it restored fitness, fur density, and renal function. No apparent toxicity in non-senescent cells.
Limitations: Single mouse study. Limited toxicology. No dose-response relationship established. No human pharmacokinetics.
View source - 2review
Senolytics: Targeting Senescent Cells for Age-Related Disease
Kirkland JL, Tchkonia T. (2020). Journal of Internal Medicine
Key findings: Comprehensive review of senolytic approaches. Places FOX04-DRI in context of broader senolytic landscape including dasatinib + quercetin, navitoclax, and fisetin. Notes that FOX04-DRI is the only peptide-based senolytic with published in vivo data.
Limitations: Review article. Notes that the field is still early and clinical translation of most senolytics remains unproven.
View source
Last reviewed: 2026-03-24 | Version: 1 | Status: Published
More in Longevity/Immune
Thymosin Alpha-1
Ta1 · Thymalfasin · Zadaxin
Thymosin alpha-1 is a peptide naturally produced by your thymus gland, which is important for immune function. A synthetic version called Zadaxin is approved in many countries around the world (but not the US) for treating hepatitis B and boosting the immune system. It is one of the most well-studied peptides available, with thousands of published research papers. Some people use it for general immune support and longevity purposes.
Epitalon
Epithalon · Epithalone · AGAG · Ala-Glu-Asp-Gly
Epitalon is a small lab-made peptide based on a substance from the pineal gland, studied primarily by Russian researchers for anti-aging purposes. The claim is that it can activate telomerase, an enzyme that helps maintain the protective caps (telomeres) on your chromosomes, potentially slowing aging. The evidence for these claims is very limited, and it is not approved anywhere as a medication. It is one of the more speculative peptides available in the grey market.
MOTS-c
Mitochondrial ORF of the 12S rRNA type-c
MOTS-c is a naturally occurring peptide produced by your mitochondria (the energy factories in your cells). It acts like an exercise signal, helping your body use sugar more efficiently and improving insulin sensitivity. Levels of MOTS-c naturally decrease as you age. A small human study showed that daily injections improved how the body handles insulin in obese men. It is still very early in research and is only available through grey-market sources.
Want to discuss this compound with a qualified physician?
The Peptide Association has verified over 160 licensed providers specializing in peptide therapy, with telehealth options available in most states.
Find a Verified Provider